Schering-Plough Licenses Late-Stage Candidate For Use In Coronary Bypass Surgery
This article was originally published in The Pink Sheet Daily
Schering intends to continue development of PeriCor’s novel drug “at an accelerated pace,” the company told “The Pink Sheet” DAILY.
You may also be interested in...
Hassan discusses changes in the industry, the importance of emerging markets such as Asia, the debate over follow-on biologics and the PDUFA reauthorization.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.